Novel anti-human ngf antibody

Abstract

To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. An anti-human NGF antibody Fab′ fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

1 - 12 . (canceled) 
     
     
         13 . An anti-human NGF antibody Fab′ fragment comprising:
 a heavy-chain fragment comprises a heavy-chain variable region comprising CDR1 consisting of amino acid sequence at position from 31 to 35 of SEQ ID NO: 6, CDR2 consisting of amino acid sequence at position from 50 to 65 of SEQ ID NO: 6, and CDR3 consisting of amino acid sequence at position from 98 to 110 of SEQ ID NO: 6; and 
 a light chain comprises a light-chain variable region comprising CDR1 consisting of amino acid sequence at position from 24 to 39 of SEQ ID NO: 4, CDR2 consisting of amino acid sequence at position from 55 to 61 of SEQ ID NO: 4, and CDR3 consisting of amino acid sequence at position from 94 to 102 of SEQ ID NO: 4. 
 
     
     
         14 . The Fab′ fragment according to  claim 13 , wherein the heavy-chain fragment comprises a heavy-chain constant region which is a human Igyl constant region. 
     
     
         15 . The Fab′ fragment according to  claim 13 , wherein the light chain comprises a light-chain constant region which is a human Igκ constant region. 
     
     
         16 . The Fab′ fragment according to  claim 13 , wherein the heavy-chain fragment comprises a heavy-chain constant region which is a human Igyl constant region, and the light chain comprises a light-chain constant region which is a human Igκ constant region. 
     
     
         17 . The Fab′ fragment according to  claim 13 , wherein the Fab′ fragment is conjugated to polyethylene glycol. 
     
     
         18 . The Fab′ fragment according to  claim 14 , wherein the Fab′ fragment is conjugated to polyethylene glycol. 
     
     
         19 . The Fab′ fragment according to  claim 15 , wherein the Fab′ fragment is conjugated to polyethylene glycol. 
     
     
         20 . The Fab′ fragment according to  claim 16 , wherein the Fab′ fragment is conjugated to polyethylene glycol.